Oncology Venture Sweden AB and its strategic partner Smerud Medical Research International AS announce that the LiPlaCis project was granted a total of about € 963 000 through the Eurostars programme for the further development of Oncology Venture's lead product LiPlaCis.
The grant will come as a joint contribution from the Norwegian Research Council and Innovation Fund Denmark.
"We appreciate this endorsement from Eurostars and this non-dilutive grant is very valuable to the LiPlaCis project", says Peter Buhl Jensen, M.D., CEO of Oncology Venture. “We believe that LiPlaCis, which has already demonstrated early signs of efficacy, can become an important treatment option for cancer patients."
SMERUD’s founder and CEO, Knut Smerud, commented: ”We are obviously very proud and pleased to see that our Eurostars proposal was ranked well by an independent board of peer reviewers. Again, we wish to emphasise that the support from the Norwegian Research Council’s Eurostars office has been tremendous throughout the entire process. SMERUD is a long-standing supporter of Eurostars as an unrivalled and excellent grant system for smaller, R&D-intensive companies in Europe."